Skip Ribbon Commands
Skip to main content
Home Administrative Billing & Reimbursement BlueCard® Health and Wellness Medical PEAR portal Pharmacy Products Quality Management

Updates to the list of specialty drugs that require precertification

January 30, 2018

Effective March 1, 2018, new precertification requirements will go into effect for Independence commercial and Medicare Advantage HMO and PPO members for the following specialty drugs that are eligible for coverage under the medical benefit:

  • Durolane® (hyaluronic acid)
  • IxifiTM (infliximab-qbtx)
  • Lutathera (lutetium [177Lu] oxodotreotide)
  • OgivriTM (trastuzumab-dkst)
  • PemfexyTM (pemetrexed)
  • TriViscTM (sodium hyaluronate)
These changes will be reflected in an updated precertification requirement list, which will be posted to our website prior to these changes going into effect. The availability of the updated precertification list will be announced in a future Partners in Health UpdateSM article.


This content was prepared for the Provider News Center and may not be reproduced in any way without the express written permission of Independence Blue Cross. Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association.
Connect with us     Facebook     Twitter     Flickr     YouTube     Walk the Talk    Independence Pinterest    Independence LinkedIn    Independence Instagram Site Map        Anti-Fraud        Privacy Policy        Legal        Disclaimer
© 2023 Independence Blue Cross.
Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association, serving the health insurance needs of Philadelphia and southeastern Pennsylvania.